Camp4 Therapeutics Corp. 10-Q Summary: Q1 2026
Business Context and Reporting Period
Camp4 Therapeutics Corp. (CAMP) is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to treat genetic diseases. The reporting period covers the three months ended March 31, 2026. The Company is classified as an emerging growth company and a smaller reporting company. Its lead product candidate, CMP-002, targets SYNGAP1-related disorder, with a global Phase 1/2 clinical trial planned for the second half of 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $1.3 million | $0.9 million |
| Net Loss | $(18.3) million | $(12.4) million |
| Net Loss Per Share (Basic/Diluted) | $(0.32) | $(0.62) |
| Operating Cash Flow | $(11.0) million | $(14.3) million |
| Cash and Cash Equivalents (End of Period) | $99.2 million | $65.7 million |
| Working Capital | $85.6 million | N/A |
| Derivative Tranche Liability | $50.9 million | $0.0 million |
Note: The filing does not provide explicit gross margin or operating margin percentages due to the pre-revenue nature of product sales and significant non-cash expenses.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $0.4 million (51%) primarily due to the recognition of $1.2 million from a new collaboration agreement with GlaxoSmithKline (GSK) entered in December 2025. This offset the termination of the BioMarin agreement.
- Net Loss Expansion: Net loss increased by $5.9 million. This was driven largely by a $6.2 million non-cash expense related to the change in fair value of a derivative tranche liability associated with a private placement.
- Operating Expenses: Total operating expenses increased slightly by $0.4 million. Research and Development (R&D) expenses remained flat at $10.2 million, while General and Administrative (G&A) expenses rose by $0.4 million due to increased personnel costs and professional fees.
- Liquidity: Cash balances increased significantly from the prior year due to capital raised in late 2025 (Private Placement and Underwritten Offering), despite ongoing operating cash burn.
Guidance, Outlook, and Risks
- Outlook: Management estimates current cash resources ($99.2 million) are sufficient to fund operations into 2028. The Company plans to initiate a global Phase 1/2 trial for CMP-002 in the second half of 2026.
- Collaborations: The GSK agreement includes a $17.5 million upfront payment (recognized over time) and potential milestones up to $440 million. The Fulcrum Therapeutics agreement was terminated for convenience in April 2026, ending future revenue potential from that deal.
- Derivative Liability: A significant contingent liability exists for a potential second closing of a private placement. This liability is valued at $50.9 million and is subject to fair value adjustments based on stock price and regulatory milestones.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital if needed, reliance on third-party manufacturers, and the potential inability to maintain orphan drug exclusivity.
Investor Verification Checklist
- Cash Runway: Verify the $99.2 million cash balance against the projected burn rate to confirm the "into 2028" liquidity estimate.
- Derivative Liability Triggers: Review the specific conditions for the $50.9 million derivative tranche liability (stock price threshold of $7.50 and regulatory milestones) to assess potential dilution or cash inflow scenarios.
- GSK Revenue Recognition: Confirm the cost-to-cost method used for recognizing the $17.5 million GSK upfront payment and the timeline for full recognition.
- Clinical Timeline: Monitor the status of regulatory filings in Australia and other jurisdictions for the CMP-002 Phase 1/2 trial initiation.
- Lease Obligations: Review the details of the new Watertown lease and the modified Cambridge lease to understand future fixed cost commitments.